on September 11, 2003
Published online before print September 11, 2003, doi: 10.1161/01.STR.0000091396.95360.E1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 4, 2003
From the University of Toronto, Department of Medicine (Division of Neurology), Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada (S.B.); University of Texas Health Sciences Center at San Antonio and Veterans Administration Hospital, San Antonio, Tex (G.C.R.); Memory Disorders Program, Department of Neurology, University of Virginia, Charlottesville (D.S.G.); Butler Hospital, Brown Medical School, Providence, RI (S.S.); Department of Rehabilitation and Aged Care, Repatriation General Hospital, Daw Park, South Australia, Australia (J.H.); University of Manchester and Wythenshawe Hospital, Manchester, UK (A.B.); and Eisai Inc, Teaneck, NJ (C.P., D.K., R.P.). * To whom correspondence should be addressed. E-mail: ray_pratt{at}eisai.com.
Background and Purpose--Clinical observations suggest that patients with vascular dementia (VaD) may benefit from treatment with cholinesterase inhibitors. This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD. Methods--Patients (n=603; mean age, 73.9 years; 55.2% men) with probable (70.5%) or possible (29.5%) VaD, according to criteria of the National Institute of Neurological Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN), were randomized to 24 weeks of treatment with donepezil 5 mg/d (n=198), donepezil 10 mg/d (5 mg/d for first 28 days; n=206), or placebo (n=199). Analyses were based on the intent-to-treat population. Results--At week 24, both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer's Disease Assessment Scale-cognitive subscale (mean change from baseline score effect size: donepezil 5 mg/d, -1.90; P=0.001; donepezil 10 mg/d, -2.33; P<0.001). Significant improvements in patients' global function were seen versus placebo at week 24 (observed cases), on the Clinician's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d (P=0.014), and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d (P=0.007). Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer's Disease Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: donepezil 5 mg/d, -1.31, P=0.02; donepezil 10 mg/d, -1.31, P=0.02). Donepezil was well tolerated. Withdrawal rates due to adverse events were relatively low (placebo, 11.1%; donepezil 5 mg/d, 11.1%; donepezil 10 mg/d, 21.8%; P=0.005 versus placebo). Conclusions--These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition.
Accepted on June 20, 2003
Efficacy and Tolerability of Donepezil in Vascular Dementia. Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial
Sandra Black FRCPC;
Key words: dementia • donepezil • randomized controlled trials
This article has been cited by other articles:
 |
|
 |
|
  Jay Cheol Kwon, Eung Gyu Kim, Jae Woo Kim, Oh Dae Kwon, Bong Goo Yoo, Hyon Ah Yi, Nack Cheon Choi, Seon Young Ahn, Byung Hwa Lee, Myong Jin Kang, et al. A Multicenter, Open-Label, 24-Week Follow-Up Study for Efficacy on Cognitive Function of Donepezil in Binswanger-Type Subcortical Vascular Dementia American Journal of Alzheimer's Disease and Other Dementias, August 1, 2009; 24(4): 293 - 301. [Abstract] [PDF]
|
|
|
|
 |
|
 C. H Rojas-Fernandez and P. Moorhouse Current Concepts in Vascular Cognitive Impairment and Pharmacotherapeutic Implications Ann. Pharmacother., July 1, 2009; 43(7): 1310 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Viswanathan, W. A. Rocca, and C. Tzourio Vascular risk factors and dementia: How to move forward? Neurology, January 27, 2009; 72(4): 368 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med, March 4, 2008; 148(5): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline Ann Intern Med, March 4, 2008; 148(5): 379 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Modrego, C. Rios, J. M. Perez Trullen, J. M. Errea, M. J. Garcia-Gomara, and S. Sanchez The Cerebrovascular Pathology in Alzheimer's Disease and Its Influence on Clinical Variables American Journal of Alzheimer's Disease and Other Dementias, March 1, 2008; 23(1): 91 - 96. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Schneider, Z. Arvanitakis, W. Bang, and D. A. Bennett Mixed brain pathologies account for most dementia cases in community-dwelling older persons Neurology, December 11, 2007; 69(24): 2197 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Auchus, H. R. Brashear, S. Salloway, A. D. Korczyn, P. P. De Deyn, C. Gassmann-Mayer, and For the GAL-INT-26 Study Group Galantamine treatment of vascular dementia: A randomized trial Neurology, July 31, 2007; 69(5): 448 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Behl, C. Bocti, R. H. Swartz, F. Gao, D. J. Sahlas, K. L. Lanctot, D. L. Streiner, and S. E. Black Strategic Subcortical Hyperintensities in Cholinergic Pathways and Executive Function Decline in Treated Alzheimer Patients Arch Neurol, February 1, 2007; 64(2): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Keverne, W. C. R. Low, I. Ziabreva, J. A. Court, A. E. Oakley, and R. N. Kalaria Cholinergic Neuronal Deficits in CADASIL Stroke, January 1, 2007; 38(1): 188 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Burns and J. O'Brien Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology J Psychopharmacol, November 1, 2006; 20(6): 732 - 755. [Abstract] [PDF]
|
|
|
|
 |
|
 M. R. Farlow Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease Mayo Clin. Proc., October 1, 2006; 81(10): 1350 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Knopman Dementia and Cerebrovascular Disease Mayo Clin. Proc., February 1, 2006; 81(2): 223 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sachdev, H. Brodaty, M. J. Valenzuela, L. Lorentz, and A. Koschera Progression of cognitive impairment in stroke patients Neurology, November 9, 2004; 63(9): 1618 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Ajilore and A. Kumar Delirium and Dementia Focus, April 1, 2004; 2(2): 210 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ihara, H. Tomimoto, K. Ishizu, T. Mukai, H. Yoshida, N. Sawamoto, M. Inoue, T. Doi, K. Hashikawa, J. Konishi, et al. Decrease in Cortical Benzodiazepine Receptors in Symptomatic Patients With Leukoaraiosis: A Positron Emission Tomography Study Stroke, April 1, 2004; 35(4): 942 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Erkinjuntti, G. Roman, S. Gauthier, H. Feldman, and K. Rockwood Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment Stroke, April 1, 2004; 35(4): 1010 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Bowler Vascular Cognitive Impairment Stroke, February 1, 2004; 35(2): 386 - 388. [Full Text] [PDF]
|
|
|
|
 |
|
 Is Donepezil Beneficial for Patients with Vascular Dementia? Journal Watch Neurology, January 29, 2004; 2004(129): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Minerva BMJ, October 18, 2003; 327(7420): 938 - 938. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Bonelli Editorial Comment--How to Treat Vascular Dementia? Stroke, October 1, 2003; 34(10): 2331 - 2332. [Full Text] [PDF]
|
|